Specific antibody responses were assessed in pigs immunized with the Taenia solium vaccine TSOL18. Anti-TSOL18 responses were compared 2 weeks after secondary immunization, where the interval between primary and secondary immunization was 4, 8, 12, 16 or 20 weeks. All animals responded to the vaccine and there was no diminution in antibody responses in animals receiving their second injection after an interval up to 20 weeks. Pigs receiving vaccinations at an interval of 12 weeks developed significantly increased antibody responses compared with animals receiving immunizations 4 weeks apart (P = 0·046). The ability to deliver TSOL18 vaccination effectively where the revaccination schedule can be delayed for up to 12-16 weeks in pigs increases the options available for designing T. solium control interventions that incorporate TSOL18 vaccination.
I N T R O D U C T I O N
Taenia solium is the aetiological agent of neurocysticercosis in humans and may be associated with as many as 29% of cases of seizure disorders in endemic areas (Ndimubanzi et al. 2010) . Taenia solium has been identified as one of a small number of human disease causing agents that have the potential to be eradicated (Anonymous, 1992; Schantz et al. 1993) . The World Health Organization identifies neurocysticercosis as a Neglected Tropical Disease and has prioritized T. solium as the focus for new control initiatives (World Health Organization, 2015) .
The full life cycle of T. solium is only perpetuated among poor people living in the world's poorest countries, where pigs roam freely and human defecation occurs in places where pigs have access to their faeces. A number of potential interventions are available for T. solium; however few, if any, specific interventions have led to a sustained decrease in the parasite's transmission (Lightowlers, 2013) .
Pigs act almost exclusively as the natural animal intermediate host for T. solium. Two key intervention measures have been developed for pigs that have the potential to prevent T. solium transmission and thereby break the parasite's life cycle. Treatment of infected pigs with 30 mg kg −1 oxfendazole kills all cysticerci present in the muscle tissues (Gonzalez et al. 1997; Sikasunge et al. 2008) . Vaccination of pigs with the TSOL18 recombinant antigen induces a high level of protection from subsequent exposure to the parasite (Flisser et al. 2004; Gonzalez et al. 2005) . In a field trial carried out in Cameroon, a combination of both TSOL18 vaccination and a single treatment of pigs with oxfendazole eliminated T. solium transmission (Assana et al. 2010) .
A limitation to interventions for T. solium that target pigs is that swine do not generally have a breeding season and hence new, susceptible individuals are born constantly into the pig population. There remains a gap in knowledge concerning the principles about how to apply vaccination and chemotherapy in pigs under field conditions in a way that would be effective, feasible and sustainable, and which could be adapted to take into account local cultural and pig management practices. In a review of the predicted effectiveness of a number of potential intervention scenarios for pigs, Lightowlers (2013) identified a schedule involving 4-monthly treatment of pigs with both TSOL18 and oxfendazole as being likely to achieve a high level of disease control, whilst minimizing the number of interventions that would be required on an annual basis. However, it was not possible at that time to recommend a vaccination scenario involving an interval of more than 4 weeks because there was no knowledge about whether or not a longer interval between primary and secondary immunizations with TSOL18 would lead to an adequate immune response to the vaccine. The available evidence indicates that a principal, if not the only, immune mechanism induced in pigs by the TSOL18 vaccine is the lysis of the early developing parasite by specific circulating antibody and complement (Lightowlers, 2006) . Specific antibody titres to TSOL18 have been used to evaluate responses to the vaccine that are associated with protection (Kyngdon et al. 2006; Assana et al. 2010 ).
Here we present the results of an immunization trial carried out in pigs where the animals received booster immunizations at different time intervals after the primary vaccination, and evaluate the different vaccination schedules by assessing the anti-TSOL18-specific antibody titres that were induced.
M A T E R I A L S A N D M E T H O D S

Pigs
Fifty, healthy Landrace-Pietran cross pigs approximately 12 weeks of age, comprising half-male and half-female animals were allocated randomly to 5 equal treatment groups, T1-T5. The animals were given feed and water ad libitum and housed indoors at a research farm under commercial-style hygienic conditions. Group sizes were the determined based on the prior research (Kyngdon et al. 2006) where 34 pigs developed a geometric mean anti-TSOL18 titre of 4634 (geometric S.D. = 0·978); we estimated that to have 80% power and 95% confidence interval (CI) of detecting a statistically significant difference, if there was a 4-fold difference between any of the treatment groups and the control group (interval between primary and secondary immunization of 28 days), we would require a minimum of 9 animals per treatment group. Allowing for inaccuracy in the assumptions underlying these estimates and/or the death of animals, we elected to allocate 10 pigs per treatment group.
TSOL18 vaccine
The TSOL18 cDNA sequence was cloned into Pichia pastoris GS115 using standard protocols (Invitrogen, USA). Secreted TSOL18 protein was harvested following P. pastoris bioreactor culture in fermentation basal salts media (Stratton et al. 1998 ). The culture supernatant was passed through a series of filters to remove yeast solids, concentrated by tangential flow filtration and dia-filtered using phosphate-buffered saline. Filter sterilized TSOL18 antigen was quantified by Coomassie dye-binding assay and densitometry of Coomassie-stained SDS polyacrylamide gels. Vaccine was prepared as a 1 mL dose containing 150 µg TSOL18 protein plus ISA206 adjuvant (SEPPIC) and 0·01% Thiomersol.
Vaccinations and sera
All pigs received a primary immunization intramuscularly in the neck on day 0. The five different treatment groups received identical secondary immunizations after 4, 8, 12, 16 or 20 weeks (T1-T5, respectively). Serum samples were obtained from each animal prior to vaccination and 2 weeks after the second immunization and were stored frozen for up to 9 months at −20°C or below, prior to being assayed in enzyme-linked immunosorbent assay (ELISA). Experimental procedures were consistent with the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes.
ELISA and statistical analyses
Anti-TSOL18-specific IgG titres were determined using a TSOL18 maltose-binding protein fusion as antigen and serial serum dilutions at 1:100, essentially as described by Kyngdon et al. (2006) . Antibody titres were compared between groups by comparing log 2 -transformed (geometric) mean titres for the treatment groups followed by linear regression with back-transformation of results for interpretation, and making no distributional assumptions with the Wilcoxon rank sum test on the raw data. R E S U L T S All animals were serologically negative (optical density <1·0 at 1:200 dilution) prior to vaccination. Anti-TSOL18-specific antibody titres in individual animals 2 weeks after the second vaccination with TSOL18 are detailed in Table 1 and Fig. 1 , and the data summarized in Table 2 . All animals exhibited an anamnestic response after receiving their second vaccination. Antibody titres in groups receiving the second immunization more than 4 weeks after the primary immunization developed higher mean titres than pigs receiving their two immunizations 4 weeks apart. Comparison of antibody titres between animals receiving their second injection after an interval of 4 weeks, with groups receiving their second immunization at a later time point are presented in Table 3 . Animals immunized at an interval of 12 weeks had 3·1 times the antibody titre of those immunized at an interval of 4 weeks (95% CI: 1·02, 9·38; P = 0·046; Wilcoxon rank sum test P = 0·049). Other comparisons were not statistically significant.
D I S C U S S I O N
Similar anti-TSOL18 antibody titres were recorded for pigs that received their second TSOL18 immunizations at intervals of 4-20 weeks to the anti-TSOL18 titres recorded in pigs involved in previous studies (Kyngdon et al. 2006; Assana et al. 2010) . Until now, results have been published from 5 different TSOL18 vaccine trials in pigs that have involved an experimental challenge infection with T. solium eggs, as well as two field trials with the vaccine (Lightowlers, 2013) . The immunization protocol used in these trials has involved, predominantly, two immunizations given at an interval of 4 weeks or less. While this vaccination schedule is extremely effective in inducing protective immune responses, implementing it in pigs in communities where T. solium is transmitted would be likely to present logistical difficulties. As the full lifecycle of T. solium is transmitted almost exclusively among the poorest people living in the poorest countries, the major challenges for control measures involve minimizing cost while maximizing effectiveness and sustainability. The availability of more flexible vaccination schedules using TSOL18 would address some of the logistical difficulties associated with implementation of pig vaccination for T. solium control. New opportunities have been created for controlling T. solium transmission by pigs following development of the TSOL18 vaccine and discovery of the cystocidal effects of oxfendazole (Gonzales et al. 1996) ; however, it remains unclear what would be the most effective method to apply these tools. The TSOL18 vaccine is effective in preventing new T. solium infections in vaccinated animals; however, the vaccine is not expected to affect T. solium cysticerci that may be already present in an animal's tissues when it is vaccinated (Lightowlers, 2010) . Treatment of pigs with 30 mg kg −1 oxfendazole will kill all cysticerci present in the muscle tissues (Gonzales et al. 1996; Sikasunge et al. 2008 ). However, a 21-day withholding period is required after treatment of pigs with oxfendazole from the only current supplier of oxfendazole registered for use in pigs for treatment of cysticercosis (MCI Santé Animale, Morocco). Compliance with the withholding period would be unlikely in the poor and poorly educated communities where control of T. solium transmission is needed. In an experimental field trial, Assana et al. (2010) used a combination of vaccination and a single oxfendazole treatment, which eliminated T. solium transmission by the animals involved in the trial. The combined use of both vaccination and oxfendazole treatment in young pigs avoided the difficulties created by the requirement for a withholding period after oxfendazole treatment because use of the drug was restricted to very young animals that were unlikely to be consumed. However, Assana et al. (2010) used a vaccination schedule, two doses 4 weeks apart, based on previous experimental challenge vaccine trials; one which might be difficult to implement as part of an on-going T. solium control programme. Here we have shown that antibody responses to the TSOL18 vaccine are not diminished in pigs in which the secondary immunization is given up to 20 weeks after the primary injection of vaccine. Indeed responses to TSOL18 are significantly greater in pigs receiving two immunizations 12 weeks apart, compared with the responses seen in animals immunized at a 4 weekly interval.
Antibody responses in pigs following two immunizations with TSOL18 given 1 month apart have been described, as have the responses seen in animals in each of the vaccination trials that have involved experimental challenge infections with T. solium (Kyngdon, 2005 (Kyngdon, , 2006 . There is no clear relationship between the peak IgG antibody titre raised to TSOL18 and the level of protection observed in individual pigs. However, all animals in all experiments have been either completely protected against infection or almost completely protected. The lowest peak anti-TSOL18 antibody titre recorded for any of the vaccinated and protected animals was 700 (Kyngdon et al. 2006) . The rate of decline in the IgG titre seen each week following a peak antibody titre determined 2 weeks after the second injection in pigs not exposed to T. solium infection (Kyngdon, 2005) is described by the equation:
Titre ¼ 10 ½À0Á11589 Ã ðweek À 2Þ × week 2 titre ð Þ
In the study described here, the group of pigs which received vaccinations 12 weeks apart developed a mean peak antibody titre of 10 290. This would be predicted to provide a titre of ⩾700 for 12 weeks following the second immunization. Protection of at least this duration is also indicated by the results obtained during the TSOL18 field trial undertaken in Cameroon. In that trial, the pigs which were vaccinated at approximately 2 and 3 months of age were protected completely against infection with T. solium caused by natural exposure to the parasite's eggs at least until they received a subsequent booster immunization approximately 3 months later (Assana et al. 2010) . Hence, the antibody response induced in pigs following immunizations with TSOL18 that were given at approximately 3 monthly intervals would be predicted to provide continuing protection for pigs after the second injection. This prediction will be tested in field studies involving local pigs breeds naturally exposed to T. solium infection. The data presented here support the likelihood that TSOL18 vaccination could be applied effectively in pigs where the interval between primary and secondary immunizations is 3-4 months. This finding increases the options available for designing T. solium intervention programs that use the vaccine and suggests that a 3-or 4-monthly intervention schedule, as proposed by Lightowlers (2013) , may be effective for prevention of T. solium transmission by pigs.
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